雷替曲塞联合奥沙利铂治疗晚期大肠癌的效果  

Effect of raltitrexed combined with oxaliplatin in the treatment of advanced colorectal cancer

作　　者：邹德辉 ZOU De-hui(Department of Oncology,Jianping County Hospital,Chaoyang 122400,China)

机构地区：[1]辽宁省朝阳市建平县医院肿瘤内科,122400

出　　处：《中国实用医药》2021年第24期139-141,共3页China Practical Medicine

摘　　要：目的对雷替曲塞联合奥沙利铂治疗晚期大肠癌的效果进行探讨。方法36例晚期大肠癌患者作为研究对象,按照治疗方法不同分为对比组与研究组,各18例。对比组患者采用氟尿嘧啶+亚叶酸钙+奥沙利铂常规化疗方案,研究组患者则接受雷替曲塞联合奥沙利铂进行治疗。对比两组临床疗效、疾病控制情况及化疗期间不良反应发生情况。结果研究组总有效率及疾病控制率分别为66.67%、94.44%,均高于对比组的33.33%、66.67%,差异有统计学意义(P<0.05)。研究组不良反应发生率为16.67%,低于对比组的50.00%,差异有统计学意义(P<0.05)。结论晚期大肠癌患者接受雷替曲塞联合奥沙利铂进行治疗,疗效更高,同时用药相对更安全,对提升患者生存质量可产生积极效应,具有应用价值,值得大力推广。Objective To discuss the effect of raltitrexed combined with oxaliplatin in the treatment of advanced colorectal cancer.Methods A total of 36 patients with advanced colorectal cancer as study subjects were divided into control group and research group according to different treatment methods,with 18 cases in each group.The control group was treated with conventional chemotherapy of fluorouracil,calcium folinate and oxaliplatin,and the research group was treated with raltitrexed and oxaliplatin.The clinical efficacy,disease control and occurrence of adverse reactions during chemotherapy were compared between the two groups.Results The total effective rate and disease control rate of the research group were 66.67%and 94.44%,which were higher than 33.33%and 66.67%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the research group was 16.67%,which was lower than 50.00%of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of raltitrexed and oxaliplatin has high efficacy and safety on patients with advanced colorectal cancer,and it has a positive effect on improving the quality of life of patients,which is worthy of promotion.

关 键 词：雷替曲塞 奥沙利铂 晚期大肠癌 临床疗效 

分 类 号：R735.34[医药卫生—肿瘤]